Avadel Pharmaceuticals plc (AVDL) EPS Estimated At $-0.30; FUNCOM NV ORDINARY SHARES (FCMKF) Shorts Decreased By 35.71%

April 7, 2018 - By Kurt Siggers

Funcom N.V. (OTCMKTS:FCMKF) Logo

Analysts expect Avadel Pharmaceuticals plc (NASDAQ:AVDL) to report $-0.30 EPS on May, 8.They anticipate $0.56 EPS change or 215.38% from last quarter’s $0.26 EPS. After having $-0.28 EPS previously, Avadel Pharmaceuticals plc’s analysts see 7.14% EPS growth. The stock decreased 0.27% or $0.02 during the last trading session, reaching $7.38. About 374,004 shares traded. Avadel Pharmaceuticals plc (NASDAQ:AVDL) has declined 26.36% since April 7, 2017 and is downtrending. It has underperformed by 37.91% the S&P500.

FUNCOM NV ORDINARY SHARES (OTCMKTS:FCMKF) had a decrease of 35.71% in short interest. FCMKF’s SI was 900 shares in April as released by FINRA. Its down 35.71% from 1,400 shares previously. With 2,900 avg volume, 0 days are for FUNCOM NV ORDINARY SHARES (OTCMKTS:FCMKF)’s short sellers to cover FCMKF’s short positions. It closed at $2.27 lastly. It is down 0.00% since April 7, 2017 and is . It has underperformed by 11.55% the S&P500.

Funcom N.V. develops and publishes massively multiplayer online games for PCs and consoles worldwide. The company has market cap of $173.84 million. It operates through Online Games and Offline Games divisions. It has a 25.51 P/E ratio. It offers approximately 27 game titles across various genres and gaming platforms; single-player classics; and console games.

Avadel Pharmaceuticals PLC identifies, develops, and commercializes pharmaceutical products for primary care and sterile injectable markets in the United States, France, and Ireland. The company has market cap of $280.09 million. The company's owns and develops drug delivery platforms, such as Micropump, a microparticulate system that allows the development of modified and/or controlled release of solid and oral dosage formulations of drugs; LiquiTime, which allows development of modified/controlled release liquid suspension formulations; Trigger Lock that allows development of abuse-deterrent modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, a hydrogel depot technology that allows the development of extended/modified release of injectable dosage formulations of drugs. It has a 4.53 P/E ratio. The Company’s lead products include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection used to treat hypotension; and Akovaz, an ephedrine sulfate injection.

Avadel Pharmaceuticals plc (NASDAQ:AVDL) Ratings Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>